ReviewAdvanced materials (Deerfield Beach, Fla.)2026
Tailoring Advanced Metal-Based Nanomedicines for Adaptable Nanodynamic Disease Therapies and Theranostics.
Review in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Poly(Amino Acid) Coordination Nanosonosensitizer as a ROS Amplifier for Enhanced Sonodynamic-Chemodynamic Therapy.Macromolecular bioscience · 2026Article
- A "metabolic dual-clamp" strategy for glucose metabolism blockade and cascade-amplified tumor immunotherapy.Materials today. Bio · 2026Article
- Where and when to strike: Spatiotemporally controlled smart nanomedicines for precision antibacterial therapy.Acta pharmaceutica Sinica. B · 2026Review
- Cationic lipid-based nanoparticles for therapeutic delivery in cancer treatment: physicochemical characteristics, therapeutic cargos, and clinical potential.Applied microscopy · 2026Review
- A biomimetic magnetic MOF-based nanoplatform for HMaterials today. Bio · 2026Article
- Smart Nanoformulations for Oncology: A Review on Overcoming Biological Barriers with Active Targeting, Stimuli-Responsive, and Controlled Release for Effective Drug Delivery.Pharmaceutics · 2026Review
- Tailoring Advanced Metal-Based Nanomedicines for Adaptable Nanodynamic Disease Therapies and Theranostics.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Nanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy.International journal of nanomedicine · 2026Review
- Clove-mediated green synthesis of silver nanoparticles andFrontiers in microbiology · 2026Article
- Precision Multimodal Nanodynamic Therapy for Lung Cancer: From Tumor Microenvironment-Responsive Platforms to Cell-Death Reprogramming and Immune Remodeling.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Advanced metal-based nanomaterials (MBNs) represent a dynamic frontier in nanomedicine, offering a versatile platform for next-generation diagnostics and therapeutics. Their tunable structures and catalytic, optical, and magnetic properties enable diverse nanodynamic therapies (NDTs), including photodynamic, chemodynamic, sonodynamic, thermodynamic, piezoelectric, radiodynamic, and magnetodynamic modalities. In addition to the well-established tumor ablation, MBNs also feature potent antimicrobial and antiviral activity, functioning via reactive oxygen species generation, immune modulation, and biofilm disruption. Recent developments in metal-organic frameworks, metal-phenolic networks, and 2D metal nanosheets have expanded the toolkit for precision drug delivery, imaging-guided therapy, and bioresponsive release strategies. This comprehensive review highlights the structural design principles, therapeutic mechanisms, and versatile biomedical applications of emerging MBN platforms, emphasizing synergistic treatment strategies and their role in overcoming hypoxia, multidrug resistance, and immunosuppression. Despite their promise, clinical translation remains hindered by unresolved issues in long-term biosafety, biodegradation, and scalable manufacturing. Future efforts are expected to focus on tailoring intelligent nanostructures with optimized pharmacokinetics, integrating multimodal imaging with real-time therapeutic feedback, and ensuring regulatory compliance. Continued innovation at the interface of materials science, biology, and medicine will be essential for transforming MBN-based systems into clinically viable tools for oncology, infectious disease control, and personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.